GBI Research, March 2010, Pages: 54
that are driving the global HPAPIs market.
- Design and develop your product development, marketing and salesstrategies.
- Develop market-entry and market expansion strategies.
- Identify key companies best
FirstWord Publishing, Jan 2012, Pages: 42
should the branded industry respond?
- How will the biosimilars industry evolve and what forces will shape it?
Who Would Benefit From This Report?
- Executive Management
- Sales and Marketing Executives
Decision Resources, Inc., Nov 2011
’s Inroads into Generics
- Commodity Generics vs. Branded Generics
- Big Pharma’s Recent Strategic Generics Initiatives
Big Pharma Diversification Strategies
- Imminent Loss of Substantial Brand Sales
Business Insights, Sep 2006, Pages: 126
technologies that are enabling personalized healthcare to move into mainstream medicine.
New opportunities in infectious disease testing, molecular oncology and pharmacogenomics are explored in detail
Decision Resources, Inc., April 2011, Pages: 41
to the rapid growth of many Asian economies, most pharmaceutical companies are taking a long hard look at Asia-Pacific markets to chart a course toward increasing global and regional drug sales. What information
Cutting Edge Information, July 2010, Pages: 203
1.35: Percentage of Companies with a SalesForce in a Therapeutic Area
Figure 1.36: Ratio of Sales Reps to MSLs by Therapeutic Area
Figure 1.37: Ratio of Sales Reps to MSLs by Therapeutic Area (cont
Bioseeker, Sep 2007, Pages: 500
their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing
MP Advisors, Jan 2011, Pages: 391
- Mandatory GLP Norms - Fresh Salvo
- Table 6: Indian Cos. Continue To Invest In SalesForce Expansion
Acquisition - Can it Be another Stock Driver?
Manufacturing Alliances - Generics to Gain The Most
Datamonitor, July 2010, Pages: 111
Opportunities and threats
Opportunity 1: aging population will result in increasing cancer incidence
Opportunity 2: oncology therapy sales continue to experience strong growth
Opportunity 3: high levels
Datamonitor, Aug 2010, Pages: 132
class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.
Scope
-Forecast sales
Datamonitor, July 2010, Pages: 114
Opportunity 1: aging population will result in increasing cancer incidence
Opportunity 2: oncology therapy sales continue to experience strong growth
Opportunity 3: high levels of unmet need
Threat 1: Pharma
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
: An Insight 13
Table 4: Growing Number of Biomarker Deals (includes
corresponding Graph/Chart) 13
Table 5: Competitive Strategy Mix in the Global Oncology
Biomarkers Market (includes corresponding Graph
Decision Resources, Inc., Aug 2010, Pages: 42
Economic pressures have forced Big Biotech companies to reevaluate their business strategies in order to minimize costs and prioritize therapy areas that will drive top-line growth. In this report
MCD Group LLC, Jan 2011, Pages: 203
to medium-sized salesforces that promote products with annual sales of less than $200 million, although there are exceptions. Purdue Pharma for example, is a fully integrated specialty pharmaceutical company
Datamonitor, Oct 2008, Pages: 144
: Sales and marketing assistance is the main reason biotechs engage in M&As 60
Figure 19: Antibodies are the driving force behind M&As for Big Pharma and Biotech player 63
Figure 20: Commercial benefits
TriMark Publications, July 2011, Pages: 225
.5.2 Image Quality and Hybrids
3. PET Applications: An Overview
3.1 Applications of PET and PET/CT in Oncology
3.1.1 PET/CT's Growth in Clinical Oncology in the U.S. and Europe
3.1.2 Cancer: Global
